FDA Approves First Plasmid DNA Immunotherapy for RRPOctober 31, 2026 Health 6 Views The FDA granted accelerated approval for Voceryq, the first plasmid DNA-based immunotherapy for adults with recurrent respiratory papillomatosis, a rare condition caused by HPV.
